[1] |
ZHANG Meiwei, LI Keqian, YAO Keyu, ZHU Yan.
Current Descriptions of Functions in Package Inserts of Chinese Herbal Patent Medicines
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 193-196.
|
[2] |
LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui.
Developments and Prospects of Radiopharmaceuticals in China
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42.
|
[3] |
HU Biyuan, WANG Jing, ZHENG Weiqi, HU Hongping, CHEN Yongwu.
Suicidal tendency and paresthesia induced by voriconazole: a case report
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 469-472.
|
[4] |
ZHONG Yingying, WANG Zhao, ZUO Tiantian, LI Yaolei, LI Hailiang, MA Shuangcheng.
Research progress on detection and risk assessment of exogenous heavy metals and related elements in Codonopsis Radix
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1309-1315.
|
[5] |
YANG Miao, YANG Li, ZHAO Zhigang.
Current applications and rationality of ribavirin in pediatrics in seven cities in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 408-412.
|
[6] |
LI Lan, KONG Fanyao, ZHU Ying, SHEN Lu.
Developments and Suggestions on Cosmetics Adverse Reaction Monitoring in China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 850-854.
|
[7] |
LI Jin, LANG Gang, WEI Li, QIN Zhengbi, SUN Yinxiang, LU Xiaoqin, CHEN Zhigao, LI Yunmei, LI Meijun, DENG Jianxiong.
A Prospective Study on Adverse Reactions of Cefazolin Sodium Pentahydrate for Injection
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1171-1175.
|
[8] |
WAN Kaihua, WEI Yu, XU Yuming, ZHOU Juan.
Current Status of Drug Abuse Epidemic and Intervention Research in China
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(6): 338-341.
|
[9] |
LI Jianguo, QIN Xiujun, HU Bo, GAO Jie, LI Mei, LIU Huan, AN Quan, JIN Hongtao.
Research Status and Prospect of Radiopharmaceuticals
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(1): 27-31.
|
[10] |
CAO Lujuan, LI Xinling, TIAN Chunhua, LIU Cuili, ZHAO Xia.
Current Status and Thinking of MAH on Post-marketing Adverse Drug Reaction Report of China
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(11): 658-662.
|
[11] |
ZHAO Xia, LENG Meiling, WANG Peng, LI Xinling, CAO Lujuan, TIAN Chunhua, LIU Cuili.
Research on Current Status and Countermeasures of Information Collection on Adverse Drug Reactions by Drug Manufacturers from Medical Institutions in China
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(11): 652-657.
|
[12] |
CHU Yan-qi, WANG Zhi-zhou, SHEN Jiang-hua, ZHANG Miao, ZHANG Qing-xia, ZENG Yan, YAN Su-ying.
Evaluation on Status of Therapeutic Drug Monitoring of Vancomycinin in Our Hospital Based on Therapeutic Drug Monitoring of Vancomycin of China
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(7): 435-438.
|
[13] |
WANG Zhi-ying, JIAO Can-wu.
Analysis of Infusion Solutions Clinical Application Status in Our Hospital
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(6): 373-376.
|
[14] |
ZHENG Ming-jie WANG Chun-ting.
Analysis of Status and Measures of Patient-reported Adverse Drug Reaction in China
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(10): 618-620.
|
[15] |
LI Liang-hua, DENG Jian-xiong.
The Discussion about Status and Conceptions of Adverse Drug Reaction Monitoring Institution in Prefecture-level City of Guangdong
[J]. Chinese Journal of Pharmacovigilance, 2012, 9(4): 222-223.
|